Format

Send to

Choose Destination
Biochem Biophys Res Commun. 2017 Nov 4;493(1):568-572. doi: 10.1016/j.bbrc.2017.08.151. Epub 2017 Sep 1.

TRIM25 is associated with cisplatin resistance in non-small-cell lung carcinoma A549 cell line via downregulation of 14-3-3σ.

Author information

1
Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, 400016 Chongqing, China.
2
Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, 400016 Chongqing, China. Electronic address: 923189400@qq.com.
3
Institute of Life Sciences, Chongqing Medical University, 400016 Chongqing, China. Electronic address: zouzhen@cqmu.edu.cn.

Abstract

Lung cancer, in particular, non-small cell lung cancer (NSCLC), is the leading cause of cancer-related mortality. Cis-Diamminedichloroplatinum (cisplatin, CDDP) as first-line chemotherapy for NSCLC, but resistance occurs frequently. We previously reported that Tripartite motif protein 25 (TRIM25) was highly expressed in cisplatin-resistant human lung adenocarcinoma A549 cells (A549/CDDP) in comparison with its parental A549 cells. Herein, we take a further step to demonstrate the association of TRIM25 and cisplatin resistance and also the underlying mechanisms. Knockdown of TRIM25 by RNA interference in A549/CDDP cells decreased half maximal inhibitory concentration (IC50) values and promoted apoptosis in response to cisplatin, whereas overexpression of TRIM25 had opposite effects. More importantly, we found that concomitant knockdown of 14-3-3σ and TRIM25 absolutely reversed the decreased MDM2, increased p53, increased cleaved-Capsese3 and decreased IC50 value induced by knockdown of TRIM25 individually, suggesting that TRIM25 mediated cisplatin resistance primarily through downregulation of 14-3-3σ. Our results indicate that TRIM25 is associated with cisplatin resistance and 14-3-3σ-MDM2-p53 signaling pathway is involved in this process, suggesting targeting TRIM25 may be a potential strategy for the reversal of cisplatin resistance.

KEYWORDS:

14-3-3σ; Chemoresistance; Cisplatin; NSCLC; TRIM25

PMID:
28867193
DOI:
10.1016/j.bbrc.2017.08.151
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center